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Has the randomized controlled trial (RCT) research
over the last 56 years (since antipsychotics were discov-
ered) informed us of the central practical questions the
clinician must face on how to medicate persons with
schizophrenia?Inthiseditorial,wewillconsiderthedegree
to which RCT support practice in the following areas.




5. When to change drug or augment
6. Depot medication
7. Long-term changes and cost
8. Progression
9. Other considerations
Choice of Drugs and Indication
We do not know the indication (which patient for which
drug) for one antipsychotic versus another or even that
one may be uniquely better for an individual patient.
We have some information on overall efficacy and safety,
which is a different question. Some who believed second-
generation antipsychotics (SGAs) as a group were more
efficacious than first-generation antipsychotic (FGA)
drugs were surprised when Clinical Antipsychotic Trials
in Intervention Effectiveness and Cost Utility of the Lat-
est Antipsychotic Drugs in Schizophrenia Study
1,2 found
most were not. But this was not surprising. The results of
these studies are generally consistent with both the regis-
trational and postmarketing studies,
3–5 which have failed
to demonstrate superiority for most SGAs, but agree that




all the market of FGA drugs, but there is some evidence
for SGAs.
6 Unfortunately, guidelines often ignore the ev-
idence.There is no information aboutwhen to escalate or
reduce dose. There is a limited evidence study that shows
first-episode patients require less medication.
7 Many do
use lower doses, but there are virtually no RCTs of first-
episode patients randomized to several doses. RCTs have
not established whether the sicker, the very chronic, or
the treatment-resistant patients require higher dose. It
is reasonable to expect that fast metabolizers, with lower
plasma levels, require higher doses, but this has also been
difficult to establish.
There is no evidence that a lower dose is required for
maintenance than for the acute episode. For many years,
guidelines recommended the progressive reduction of
maintenance dose. We do have some evidence on main-
tenance dose for some depot drugs, suggesting more
relapses with lower dose but little on the optimal oral
dose for either phase.
Emergency Treatment
There is some recent evidence about how to treat a psy-
chotic episode of severe agitation in the first day.
8 But we
do not know for sure whether benzodiazepines alone, or
when combined with antipsychotics, are as effective as
antipsychotics only alone for days or even a week.
Monitoring Treatment
In internal medicine, the internist may adjust the dose
or change drug based on monitoring clinical (eg, blood
pressure) or a laboratory measure of a disease-related
outcome. We do not have anything analogous in psychi-
atry. The hopes for biomarkers of therapeutic response
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403have not yet materialized. In theory, standard rating
scales such as the Positive and Negative Syndrome Scale
could be administered, but this takes too much time for
routine use in practice. A simple rating scale would be
helpful, if well standardized. It would be particularly
helpful to have RCT to show that it actually improved
outcome.
When to Change Drug or Augment?
We do not know how to define treatment failure. It is
possible that some seemingly responsive patient would
do still better on a different dose, another drug, or
augmentation.
It is possible that certain patients may do better on one
antipsychotic than another. In whom, with what drug
and when, should we change drugs? There is some evi-
dence from an RCT that patients who do not tolerate
a given antipsychotic will dislike the same drug when
readministered.
9
We have only limited and often contradictory evidence
to guide augmentation strategies. RCTs have not in-
formed us as to when, with what drug, and in which pa-
tient augmentation is useful. This said that there is some
evidence to indicate that patients who seem to have de-
pressive disorders superimposed on schizophrenia may
respond to augmentation with an antidepressant or, if re-
current, need prophylactic antidepressants.
Depot Medication
Randomized studies of depot versus oral may not yield
meaningful data because patients who do not take their
medication may not volunteer for a demanding RCT.
Long-Term Changes and Cost
Ifabetterdrugwasmoreefficaciousthananotherdrugin
one or another domain, it may take a month (or even
years) for this to translate into a measurable decrease
inreal-worldoutcomessuchasinrehospitalizations,abil-
ity to live in a less restricted setting, getting a job, quality
oflife,changingmedicalcosts,etc.Wedonothaveavalid
methodology to address most of these questions. We do
havemethodsfordeterminingpreventionofrelapseusing
survival methodologies, but this does not help with as-
sessment of functional outcomes. As each patient relap-
ses, the once initially randomized samples become no
longer randomized. Consequently, the groups become
progressively different on the variable of interest. This
confounds the findings of long-term studies. Let me illus-
trate with an exaggerated example as a thought experi-
ment: suppose a treatment for a given cancer that
cured 90% and a 10-year follow-up was done on drug
and placebo, 10% of the placebo-treated patients experi-
enced spontaneous remission of the cancer but 90% rap-
idly died; however, 90% of the drug-treated patients
recovered and 10% died. The 90% on drug and 10% re-
mitted on placebo would be doing equally well for most
of the 10 years. The cost of the placebo-treated group
would be low because 90% died. Nothing saves medical
costs like death. Outcome assessment would be meaning-
less because the groups are now nonrandom for most of
the trial. This is a systematic error.
Progression
There is evidence to suggest that schizophrenia pro-
gressesafterthefirstepisodetoworsenoverseveralyears.
Can all drugs reduce progression? Are some better than
others at this? There is insufficient evidence from RCTs
to determine whether progression can be prevented and,
if so, which is the best choice of drug.
Other Considerations
One of the functions of evidence-based medicine is to re-
mind us of the absence of evidence. Some of the areas of
ignorance can be answered by traditional randomized
studies; others require different methodologies. Some
writers claim that their recommendations are evidence
based but actually state their opinion in the absence of
evidence or the presence of evidence contradicting their
conclusions. ‘‘Not studied’’ does not indicate ‘‘dis-
proved.’’ Indeed, everyday issues addressed in clinical
practice require integration of general knowledge rather
than specifically relevant evidence for RCTs. The clini-
cian’s expertise is based on general knowledge and expe-
rience. The art of medicine is essential even in the day of
evidenced-based practice.
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